Remove Licensing Remove Treatment Remove Vaccine
article thumbnail

Vor says drug licensed from RemeGen succeeded in Sjögren’s study

BioPharma Drive: Drug Pricing

13, 2025 Ned Pagliarulo Lead Editor post share post print email license B cells, like those pictured above, malfunction in autoimmune diseases. The company laid off essentially all its staff in May, before pivoting into autoimmune disease via a licensing deal for telitacicept. Published Aug. and Europe-based firms.

article thumbnail

Nobel Prize celebrates AI’s role in protein structure innovation

Drug Target Review

Baker’s model could revolutionise drug development, synthetic biology, and nanotechnology, opening possibilities for new medical treatments, vaccines, nanomaterials, and sensors.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

2025 Merkin Prize in Biomedical Technology awarded to pioneers of CAR T-cell therapy

Broad Institute

The work of June, Levine, Rivire, and Sadelain laid the foundation for a whole new class of treatments. After their clinical results, their technology was licensed to Juno Therapeutics (later acquired by Bristol Myers Squibb.)

article thumbnail

Takeda to seek approval of new kind of narcolepsy drug after study data

BioPharma Drive: Drug Pricing

Published July 14, 2025 Ben Fidler Senior Editor post share post print email license Takeda reported positive results for oveporexton, a drug being developed for narcolepsy Type 1, on July 14, 2025. Oveporexton’s safety profile was “consistent” with what’s been observed in previous clinical tests, Takeda said. Can they keep it?

article thumbnail

Navigating Regulatory Hurdles in Drug Development

DrugBank

In 2020, the FDA halted Johnson & Johnson’s COVID-19 vaccine production at a contract manufacturing facility after discovering quality control issues. Once a drug completes Phase III trials, companies prepare a New Drug Application or Biologics License Application (BLA) for final review.

article thumbnail

FDA clears Nuvation lung cancer drug, setting up battle with Bristol Myers and Roche

BioPharma Drive: Drug Pricing

Published June 11, 2025 Ben Fidler Senior Editor post share post print email license The FDA on June 11, 2025 approved Nuvation's Ibtrozi for ROS1-positive non-small cell lung cancer.

FDA
article thumbnail

Vor, with new CEO, changes course to target autoimmune disease

BioPharma Drive: Drug Pricing

Published June 26, 2025 Gwendolyn Wu Senior reporter post share post print email license B cells, like those pictured above, malfunction in autoimmune disease. Vor Biopharma licensed a drug in June 2025 that targets proteins essential to B cell survival. But a rocky few years forced Vor to change direction. and European drugmakers.